NACLC 2022

CME Information

The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity and scientific rigor for all Continuing Medical Education (CME) activities.  

In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME defined ineligible companies. All disclosures are reviewed to identify relevant financial relationships and any conflicts of interest are mitigated before the individual can assume their role in the activity.  

Accreditation and Credit Statements

The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity has been approved for AMA PRA Category 1 Credit™.

For the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022), presenter disclosure information will be available for viewing as of September 22, 2022. Presenters are also required to include a disclosure slide listing all relevant financial relationships with commercial interests. CME related questions should be directed to IASLC at [email protected].

The IASLC 2022 North America Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer and other thoracic malignancies, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, physician assistants and nurses. The conference is also designed to provide a forum for lung cancer patients and patient advocates to receive education and share their perspectives with the lung cancer community. 

At the conclusion of this activity, participants will be able to: 

  1. Apply evidence-based recommendations and clinical practice guidelines to diagnose and treat patients with lung cancer and other thoracic malignancies. 
  2. Describe the impact of COVID-19 on lung cancer care, research, and prevention efforts. 
  3. Describe scientific advances in lung cancer and other thoracic malignancies. 
  4. Synthesize research from clinical trials and translational studies to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties. 
  5. Advocate for lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, and implementing early screening. 
  6. Engage and empower patients to become active participants in their treatment. 

The official language of the IASLC 2022 North America Conference on Lung Cancer is English. 

The information presented at the IASLC 2022 North America Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects. 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.